Provided by Tiger Trade Technology Pte. Ltd.

Clearmind Medicine, Inc.

0.6680
-0.0035-0.52%
Post-market: 0.6579-0.0101-1.51%19:59 EDT
Volume:14.79K
Turnover:9.68K
Market Cap:1.40M
PE:-0.03
High:0.6680
Open:0.6581
Low:0.6350
Close:0.6715
52wk High:52.40
52wk Low:0.5949
Shares:2.09M
Float Shares:1.78M
Volume Ratio:0.04
T/O Rate:0.83%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-24.1200
EPS(LYR):-30.3477
ROE:-119.72%
ROA:-55.21%
PB:0.17
PE(LYR):-0.02

Loading ...

Clearmind Medicine Inc - Safety Data Show No Serious Adverse Events in Second Cohort

THOMSON REUTERS
·
Feb 09

Clearmind Medicine Inc - Announces Positive Safety Results From Phase I/Iia Trial

THOMSON REUTERS
·
Feb 09

Clearmind Medicine Announces Additional Topline Positive Safety Results Reinforcing Favorable Profile of CMND-100 in Ongoing Phase I/IIa Clinical Trial

GlobeNewswire
·
Feb 09

BRIEF-Clearmind Medicine Enters Development Agreement For Intranasal Formulation Of Proprietary Nonhallucinogenic Neuroplastogen MEAI

Reuters
·
Feb 06

BUZZ-Polyrizon jumps as it teams up with Clearmind for intranasal drug delivery

Reuters
·
Feb 06

Clearmind Medicine Enters Into Development Agreement to Advance Intranasal Formulation for Its Proprietary Non-Hallucinogenic Neuroplastogen Meai

THOMSON REUTERS
·
Feb 06

Polyrizon Partners with Clearmind to Develop Intranasal MEAI Formulation

Reuters
·
Feb 06

Polyrizon Signs an Agreement to Develop Intranasal Proprietary Non-Hallucinogenic Neuroplastogen Formulation

THOMSON REUTERS
·
Feb 06

Clearmind Medicine Issues $2.5 Million in Convertible Promissory Notes

Reuters
·
Feb 05

Clearmind Medicine gibt Ausgabe von Wandelanleihen im Gesamtwert von 2,5 Millionen US-Dollar bekannt

Reuters
·
Feb 05

Clearmind Medicine welcomes inclusion of MEAI in bipartisan legislation

TIPRANKS
·
Feb 03

Clearmind Medicine erzielt Durchbruch mit MEAI in US-Gesetz für innovative Veteranen-Therapien

Reuters
·
Feb 03

Psychedelic: Clearmind completes second cohort treatment for CMND-100 trial

TIPRANKS
·
Jan 15

BRIEF-Clearmind Medicine Inc - Topline Results From Second Cohort Of CMND-100 Expected In Coming Months

Reuters
·
Jan 14

Clearmind Medicine Inc - Topline Results From Second Cohort of Cmnd-100 Expected in Coming Months

THOMSON REUTERS
·
Jan 14

Clearmind Medicine Completes Second Cohort Treatment in Phase I/IIa Trial for Alcohol Use Disorder Drug

Reuters
·
Jan 14

Clearmind Medicine Announces Successful Completion of Treatment in All Patients of the Second Cohort in Ongoing Phase I/IIa Clinical Trial for CMND-100

GlobeNewswire
·
Jan 14

Clearmind Medicine Says Nasdaq Compliance Regained on Minimum Bid Price Rule

MT Newswires Live
·
Dec 31, 2025

Clearmind Medicine Regains Compliance With Nasdaq Minimum Bid Price Requirement

THOMSON REUTERS
·
Dec 31, 2025

Clearmind Medicine Reports Positive Phase I/IIa Results for CMND-100 in Alcohol Use Disorder Trial

Reuters
·
Dec 29, 2025